Navigation Links
Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy
Date:12/4/2008

MONTPELLIER, France, Dec. 4 /PRNewswire-FirstCall/ -- A 60-year-old prostate cancer patient from Montpellier has become the first person in France to be treated using RapidArc(TM) technology from Varian Medical Systems (NYSE: VAR) for fast and precise forms of intensity modulated radiotherapy (IMRT). Each of his treatments at the CRLC Val D'Aurelle - Paul Lamarque in the city took just 75 seconds, several times faster than conventional IMRT treatments. Dr. Pascal Fenoglietto, the hospital's chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 12- 14.

"The treatments went extremely well and the patient was very pleased because compared to conventional IMRT it was three times quicker," Dr. Fenoglietto said. "We are now able to use the time we save on treatment delivery to take more images and increase the quality of our care."

"The radiation therapists were also very pleased because it is a simpler treatment for them to deliver," added Professor Jean-Bernard Dubois, head of the radiation oncology department and managing director of the hospital.

With RapidArc, Varian's Clinac(R) medical linear accelerator can target radiation beams at a tumor while making one continuous rotation around the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers because they target tumors using a complex sequence of fixed beams from multiple angles.

RapidArc technology allows more control to conform the dose more closely to the size, shape, and location of the tumor. Faster treatment also contributes to precision by reducing the time for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more e
'/>"/>

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
2. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
3. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
6. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
8. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
9. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
10. When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer
11. American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Mich. , March 27, 2015  Neogen Corporation ... LLC, has adopted a prearranged trading plan in accordance ... Herbert , Chairman and CEO of Neogen Corporation, is ... of Neogen Corporation common stock. Herbert does ... disclosure was appropriate. The filing is only for a ...
(Date:3/27/2015)... March 27, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the ... today that an Investigational New Drug (IND) application ... rheumatoid arthritis has been accepted for review by ... In September 2012, MedImmune, the global ...
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based ... and executive appointments effective immediately. , Mike Catelani will ... member of the Board of Directors. Daniel Head is ... Dowden will assume the position of Senior Director of ... Officer (COO), has been appointed to the position of ...
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... 27 Mediatech, Inc. is settling,into their brand ... land,in Prince William County. Right down the road ... joins other,biotechnology and technology companies, including ATCC in ... The brand new manufacturing plant has been ...
... Amended the Design of the Ofatumumab Pivotal Study in, ... ... 81, COPENHAGEN, September 27 Genmab A/S (OMX:,GEN) announced ... study,of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular,non-Hodgkin,s lymphoma (NHL) to ...
... for October, JACKSONVILLE, Fla., Sept. 27 ... announced today that its,performance/vitality beverage product, AQUISS(TM), will ... to the Oregon border. 7-Eleven,plans a launch of ... sampling campaign to acquaint 7-Eleven,s customers with the,technology ...
Cached Biology Technology:Mediatech Moves to Prince William County Innovation Park 2Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 2Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 3Phlo Affiliate Reports AQUISS to be Sold in 450 7-Eleven Stores 2
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... September 11, 2012 BiOptix announced continued support of the ... 2012, a leading life sciences showcase event in ... "BiOptix continues to believe in the goals and ... Rick Whitcomb, President and CEO of BiOptix.   "As ...
... a crow and it,ll remember you for years. Crows and ... with negative, as well as positive, feelings. The way the ... also appear to share, according to new research being published ... together are not unlike those that work together in mammals, ...
... found a way to prevent inflammation and bone loss ... of the enzyme GSK3b, which plays an important role ... of UofL School of Dentistry researcher David Scott, PhD, ... journal Molecular Medicine . The finding not only ...
Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2Crows react to threats in human-like way 2Crows react to threats in human-like way 3
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
...
... first biological reagent that eliminates ... not just by inhibiting growth. ... agent that can be used ... The cytotoxicity of Mynox is ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: